Patents Represented by Attorney Michelle A. Kaye
-
Patent number: 5814468Abstract: This invention relates generally to using fluorescent markers (labelled antibodies) and flow cytometry to enumerate the average number of receptors (antigen) on formed bodies (cells) in whole blood, and to evaluate the specific binding constant of the marker for the particular receptors. Mean channel fluorescence intensities of equilibrated marker-cell suspension mixtures, total concentrations of marker, and targeted cell counts obtained by established procedures are used to complete the analyses. The invention further describes a competitive binding assay between marker and unlabelled antibody for receptors shed from the surface of formed bodies into solution and receptors on the formed bodies to analyze for receptors in solution. Moreover, competitive binding assays between marker and unlabelled antibody for receptors on formed bodies in whole blood are described for determination of relative, specific, and average binding constants of unlabelled/labelled antibody for targeted receptors.Type: GrantFiled: March 27, 1996Date of Patent: September 29, 1998Assignee: Coulter International Corp.Inventors: Olavi Siiman, Alexander Burshteyn, Orlando Concepcion, Meryl Forman
-
Patent number: 5783673Abstract: A method for preparing phycobiliprotein/amine-reactive dye conjugates is disclosed in which the conjugates so prepared overcome the energy transfer/fluorescent quenching dilemma encountered in the use of prior art conjugates. A phycobiliprotein, for example, phycoerythrin or allophycocyanin, is conjugated with an amine-reactive dye, for example, Texas Red or carboxyfluorescein succinimidyl ester, in the presence of a selective salt which causes a hydrophobic intramolecular rearrangement of the phycobiliprotein thereby exposing more hydrophobic sites for binding to the amine-reactive dye. The conjugates prepared according to the invention are useful in multiple color fluorescence assays without requiring the use of multiple exciting sources.Type: GrantFiled: October 10, 1996Date of Patent: July 21, 1998Assignee: Coulter CorporationInventor: Ravinder K. Gupta
-
Patent number: 5776706Abstract: Gelatin and aminodextran coated polymer core particles useful in immunoassays and methods of making the same are disclosed. The preparation of aminodextrans having varying amounts of amine groups is also described, as is a method of crosslinking gelatin and aminodextran without the use of a stabilizer.Type: GrantFiled: March 6, 1997Date of Patent: July 7, 1998Assignee: Coulter CorporationInventors: Olavi Siiman, Alexander Burshteyn, Ravinder K. Gupta
-
Patent number: 5707877Abstract: The invention relates generally to colloidal particle having a core material and a gelatin/aminodextran coating with pendent functional groups attached thereto. Biological substances or molecules, especially monoclonal antibodies, may be attached to said particles. The monoclonal antibody containing particles are useful in a variety of positive and negative biological assays.Type: GrantFiled: June 23, 1995Date of Patent: January 13, 1998Assignee: Coulter CorporationInventors: Olavi Siiman, Alexander Burshteyn, Ravinder K. Gupta
-
Patent number: 5658741Abstract: The invention describes the use of novel aminodextran compounds containing about 5-20% by weight amine groups to bind a plurality of monoclonal antibodies. The resulting antibody-aminodextran compounds may be used to induce the activation and proliferation of selected mammalian cells. Specific examples are given using an anti-CD3 monoclonal antibody conjugated two aminodextrans containing about 5% and 16%, respectively, by weight amine groups as an agent for inducing the activation and proliferation of T cells.Type: GrantFiled: July 19, 1995Date of Patent: August 19, 1997Assignee: Coulter CorporationInventors: Wade E. Bolton, John A. Maples, Olavi Siiman, Norma Sue Kenyon, Cynthia G. Healy
-
Patent number: 5639666Abstract: A process for determining the reticulocyte population in blood samples, which process includes the use of coriphosphine O to stain reticulocytes and which process is particularly suitable for detection by flow cytometry techniques.Type: GrantFiled: June 27, 1995Date of Patent: June 17, 1997Assignee: Coulter CorporationInventor: Mark Lee Shenkin
-
Patent number: 5639620Abstract: Gelatin and aminodextran coated polymer core particles useful in immunoassays and methods of making the same are disclosed. The preparation of aminodextrans having varying amounts of amine groups is also described, as is a method of crosslinking gelatin and aminodextran without the use of a stabilizer.Type: GrantFiled: November 9, 1994Date of Patent: June 17, 1997Assignee: Coulter CorporationInventors: Olavi Siiman, Alexander Burshteyn, Ravinder K. Gupta
-
Preserved, non-infectious control cells prepared by the modulation or modification of cultured cells
Patent number: 5622855Abstract: The invention describes the preparation of preserved, non-infectious control cells. The control cells are prepared by modification, activation or otherwise changing selected normal leukocyte cells, tissue culture cells or zenogenic transplants in immunosuppressed animals to have characteristics of abnormal cells or by the addition of cells from an established cell line, which have been similarly modified or activated, to a normal leukocyte population. The preferred method of preserving the control cells is by lyophilization using an isotonic 10% trehalose solution.Type: GrantFiled: April 10, 1995Date of Patent: April 22, 1997Assignee: Coulter CorporationInventors: John A. Maples, Patricia A. Roth, Melissa J. Stiglitz -
Patent number: 5552086Abstract: The invention describes stable colloidal polymeric particles of 0.2-5.0 microns size which are coated with a first aminodextran layer and a second metallic solid layer, The metal is coated by reduction of a metallic salt or complex by the aminodextran.Type: GrantFiled: September 9, 1993Date of Patent: September 3, 1996Assignee: Coulter CorporationInventors: Olavi Siiman, Alexander Burshteyn, Marilyn Cayer
-
Patent number: 5527713Abstract: The invention describes the use of novel aminodextran compounds containing about 5-20% by weight amine groups to bind a plurality of monoclonal antibodies. The resulting antibody-aminodextran compounds may be used to induce the activation and proliferation of selected mammalian cells. Specific examples are given using an anti-CD3 monoclonal antibody conjugated two aminodextrans containing about 5% and 16%, respectively, by weight amine groups as an agent for inducing the activation and proliferation of T cells.Type: GrantFiled: July 19, 1995Date of Patent: June 18, 1996Assignee: Coulter CorporationInventors: Wade E. Bolton, John A. Maples, Olavi Siiman, Norma S. Kenyon, Cynthia G. Healy
-
Patent number: 5468849Abstract: Addition of certain tryptophan analogs to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of new rebeccamycin analogs having advantageous antitumor properties.Type: GrantFiled: March 21, 1994Date of Patent: November 21, 1995Assignee: Bristol-Myers Squibb CompanyInventors: Kin S. Lam, Daniel R. Schroeder, Jacqueline Mattei, Salvatore Forenza, James A. Matson
-
Patent number: 5466609Abstract: The invention relates generally to colloidal particle having a core material and a gelatin/aminodextran coating with pendent functional groups attached thereto. Biological substances or molecules, especially monoclonal antibodies, may be attached to said particles. The monoclonal antibody containing particles are useful in a variety of positive and negative biological assays.Type: GrantFiled: October 29, 1992Date of Patent: November 14, 1995Assignee: Coulter CorporationInventors: Olavi Siiman, Alexander Burshteyn, Ravinder K. Gupta
-
Patent number: 5437985Abstract: The method of this invention is directed to the rapid preparation of a whole blood sample for photooptical analysis. In the preferred embodiments of this method, a whole blood sample, lytic reagent system and immunological stain (optional) are contacted with the sample in a common reaction vessel (i.e. cuvette or test tube), with gentle asymmetric vortex mixing, so as to maintain the particulate matter of the sample at an essentially homogeneous concentration throughout the sample. An aliquot of the contents of the reaction vessel can, thereafter, be analyzed for identification and/or quantification of the analyte of interest.Type: GrantFiled: July 8, 1991Date of Patent: August 1, 1995Assignee: Coulter CorporationInventors: Jorge A. Quintana, Thomas R. Russell, Ronald D. Paul, Timothy J. Fischer
-
Patent number: 5409826Abstract: The invention describes the preparation of preserved, non-infectious control cells. The control cells are prepared by modification, activation or otherwise changing selected normal leukocyte cells, tissue culture cells or zenogenic transplants in immunosuppressed animals to have characteristics of abnormal cells or by the addition of cells from an established cell line, which has been similarly modified or activated, to a normal leukocyte population. The preferred method of preserving the control cells is by lyophilization using an isotonic 10% trehalose solution.Type: GrantFiled: June 8, 1993Date of Patent: April 25, 1995Assignee: Coulter CorporationInventors: John A. Maples, Patricia A. Roth, Melissa J. Stiglitz
-
Patent number: 5374711Abstract: This invention relates to novel elsamicin A derivatives wherein the 2"-amino group is selectively modified by acylation or alkylation, a process for producing said elsamicin A derivatives, an antitumor composition containing the same as the active ingredient, and a method for therapy using said compositions.Type: GrantFiled: September 15, 1993Date of Patent: December 20, 1994Assignee: Bristol-Myers Squibb CompanyInventors: Soichiro Toda, Haruhiro Yamashita, Takayuki Naito, Yuji Nishiyama
-
Patent number: 5344823Abstract: A new antitumor antibiotic designated BMY-41219 is produced by fermentation of Saccharothrix aerocolonigenes ATCC 39243. The BMY-41219 antibiotic exhibits antitumor activity.Type: GrantFiled: February 6, 1992Date of Patent: September 6, 1994Assignee: Bristol-Myers Squibb CompanyInventors: Kin S. Lam, Leonard A. McDonald, Jacqueline Mattei, Salvatore Forenza, James A. Matson
-
Patent number: 5338732Abstract: The present invention relates to a novel oral pharmaceutical composition of micronized megestrol acetate at a concentration of 15 to 150 mg/mL comprising polysorbate at a concentration of 0.005% to 0.015% weight/volume and polyethylene glycol at a concentration of 5-30% weight/volume which composition forms a stable flocculated suspension in water. The invention further comprises the micronized megestrol acetate formulation described above with added preservatives, buffers, sweeteners and flavoring agents.Type: GrantFiled: May 13, 1992Date of Patent: August 16, 1994Assignee: Bristol-Myers Squibb CompanyInventors: Anne E. Atzinger, Robert J. Bequette, Robert E. Davis
-
Patent number: 5262540Abstract: Oxazole derivatives having Formula I or II are disclosed which are useful as inhibitors of mammalian blood platelet aggregation. ##STR1## Formula I and Formula XIX compounds are those wherein n is 7-9 and R is hydrogen or lower alkyl. Formula II compounds are those wherein R is hydrogen, lower alkyl or together with CO.sub.2 is tetrazol-1-yl; R.sub.1 is phenyl or thienyl; X is a divalent connecting group selected from the group consisting of CH.sub.2 CH.sub.2, CH.dbd.CH, and CH.sub.2 O; Y is a divalent connecting group attached to the 3 or 4 phenyl position selected from the group consisting of OCH.sub.2, CH.sub.2 CH.sub.2 and CH.dbd.CH. Formula XX compounds are those wherein the OCH.sub.2 CO.sub.2 R moiety is attached to the 3 or 4 phenyl position and R is hydrogen or lower alkyl.Type: GrantFiled: May 10, 1993Date of Patent: November 16, 1993Assignee: Bristol-Myers Squibb CompanyInventor: Nicholas A. Meanwell
-
Patent number: 5256646Abstract: A novel antibiotic complex designated BU-4224V produced by fermentation of Kibdelosporangium albatum sp. nov. Strain R761-7. The complex may be separated chromatographically into bioactive components designated BU-4224V A, B.sub.1, B.sub.2, and C. The components BU-4224V B.sub.1 and B.sub.2 display both antiviral and antimicrobial activity, while component BU-4224V A has antimicrobial activity and component BU-4224V C has antiviral activity.Type: GrantFiled: July 27, 1990Date of Patent: October 26, 1993Assignee: Bristol-Myers Squibb CompanyInventors: Mitsuaki Tsunakawa, Tetsuro Yamasaki, Koji Tomita, Osamu Tenmyo
-
Patent number: 5254576Abstract: A novel series of oxazole derivatives having enhanced water solubility bioavailability and metabolic stability is disclosed in the Formula I ##STR1## X is ##STR2## R is CH.sub.2 R.sup.2, H; R.sup.1 is Ph or Th;R.sup.2 is ##STR3## H, CN, CO.sub.2 R.sup.3, or OR.sup.3 ; and R.sup.3 is H, or C.sub.1 -C.sub.4 lower alkyl;or pharmaceutically acceptable salt thereof.Type: GrantFiled: April 3, 1992Date of Patent: October 19, 1993Assignee: Bristol-Myers Squibb CompanyInventors: Jeffrey L. Romine, Nicholas A. Meanwell, Scott W. Martin